Gilead, Unitaid and the US National Institutes of Health are funding 36 ongoing studies to investigate implementation outcomes, rapid initiation and real-life use of injectable lenacapavir (LEN) for PrEP in 9 countries. Gilead’s INCLUSION program (INCLUSION Global in Africa and Asia and INCLUSION-US in the United States) accounts for 26 of these studies. This table provides details on the INCLUSION Global projects planned for 2026-2028 in 7 LEN early adopter countries. For more details on all ongoing LEN implementation studies, see our map and visit the integrated study dashboard.
Was this content helpful?
Tell us how we can improve the content.
Was this content helpful?
Thank you for your feedback!